mProX™ Human ACE2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

ACE2 (angiotensin-converting enzyme 2) has several applications related to SARS-CoV-2. In one study, computational techniques were used to design neutralizing Nbs that can effectively neutralize the receptor-binding domain (RBD) of SARS-CoV-2 variants of concern (VOCs). These engineered Nbs have the potential to be used in RBD-neutralizing assays, aiding in the development of novel treatment, prevention, and diagnostic strategies against SARS-CoV-2. Another study highlighted the role of ACE2-mediated NF-κB activation in COVID-19 patients and the potential use of NF-κB activation inhibitors for favorable prognosis. Additionally, ACE2 expression was found to be lower in the respiratory tract of dogs compared to cats, which may contribute to differences in susceptibility to SARS-CoV-2 infection between these species. Finally, ACE2-derived peptides were synthesized and evaluated for their potential to inhibit SARS-CoV-2 cell entry, showing promising results against different variants of the virus. These findings suggest that ACE2 and its derivatives have potential applications in therapeutic and diagnostic strategies against SARS-CoV-2.